Protein-coupled receptor-G-protein βγ-subunit signaling mediates renal dysfunction and fibrosis in heart failure

Journal of the American Society of Nephrology

Volumn 28, Issue 1, 2017, Pages 197-208

  Kamal, Fadia A ^a   Travers, Joshua G ^a   Schafer, Allison E ^a   Ma, Qing ^a   Devarajan, Prasad ^a   Blaxall, Burns C ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD45 ANTIGEN; CREATININE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR G PROTEIN BETA GAMMA SUBUNIT; G PROTEIN COUPLED RECEPTOR KINASE 2; GALLEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; G-PROTEIN BETA GAMMA; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTIC CONSTRICTION; ARTICLE; CELL MIGRATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HEART FAILURE; IMMUNOFLUORESCENCE; IN VITRO STUDY; INFLAMMATION; KIDNEY CORTEX; MALE; MAPK SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE INJURY; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIO-RENAL SYNDROME; COMPLICATION; KIDNEY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIO-RENAL SYNDROME; FIBROSIS; GTP-BINDING PROTEIN BETA SUBUNITS; GTP-BINDING PROTEIN GAMMA SUBUNITS; HEART FAILURE; KIDNEY; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85021849712     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015080852     Document Type: Article

References (51)

1. Smilde TD, Hillege HL, Navis G, Boomsma F, De Zeeuw D, Van Veldhuisen DJ: Impaired renal function in patients with ischemic and nonischemic chronic heart failure: Association with neurohormonal activation and survival. Am Heart J 148: 165-172, 2004
2. Hillege HL, Girbes AR, De Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210, 2000
3. Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H: Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: Implications for cardiorenal syndrome. Am J Physiol Heart Circ Physiol 302: H1884-H1893, 2012
4. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW: Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-1009, 2004
5. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004
6. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL: Worsening renal function and prognosis in heart failure: Systematic review and meta-analysis. J Card Fail 13: 599-608, 2007
7. Gärtner F, Seidel T, Schulz U, Gummert J, Milting H: Desensitization and internalization of endothelin receptor A: Impact of G proteincoupled receptor kinase 2 (GRK2)-mediated phosphorylation. J Biol Chem 288: 32138-32148, 2013
8. Kamal FA, Travers JG, Blaxall BC: G protein-coupled receptor kinases in cardiovascular disease: Why "where" matters. Trends Cardiovasc Med 22: 213-219, 2012
9. Hata JA, Koch WJ: Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease. Mol Interv 3: 264-272, 2003
10. Akhter SA, Eckhart AD, Rockman HA, Shotwell K, Lefkowitz RJ, Koch WJ: In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. Circulation 100: 648-653, 1999
11. Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D, Wong LJ, Robillard JE, Carey RM, Eisner GM, Jose PA: G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci U S A 99: 3872-3877, 2002
12. Kansra V, Hussain T, Lokhandwala MF: Alterations in dopamine DA1 receptor and G proteins in renal proximal tubules of old rats. Am J Physiol 273: F53-F59, 1997
13. Sanada H, Jose PA, Hazen-Martin D, Yu PY, Xu J, Bruns DE, Phipps J, Carey RM, Felder RA: Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension. Hypertension 33: 1036-1042, 1999
14. Sidhu A, Vachvanichsanong P, Jose PA, Felder RA: Persistent defective coupling of dopamine-1 receptors to G proteins after solubilization fromkidney proximal tubules of hypertensive rats. JClin Invest 89: 789-793, 1992
15. Uh M, White BH, Sidhu A: Alteration of association of agonist-activated renal D1(A) dopamine receptors with G proteins in proximal tubules of the spontaneously hypertensive rat. J Hypertens 16: 1307-1313, 1998
16. Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ: Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 87: 454-463, 1993
17. Morris GE, Nelson CP, Brighton PJ, Standen NB, Challiss RA, Willets JM: Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptormediated cell signaling and migration in arterial smooth muscle. Am J Physiol Cell Physiol 302: C723-C734, 2012
18. Morris GE, Nelson CP, Standen NB, Challiss RA, Willets JM: Endothelin signalling in arterial smooth muscle is tightly regulated by G proteincoupled receptor kinase 2. Cardiovasc Res 85: 424-433, 2010
19. Gao X, Wu G, Gu X, Fu L, Mei C: Kruppel-like factor 15modulates renal interstitial fibrosis by ERK/MAPK and JNK/MAPK pathways regulation. Kidney Blood Press Res 37: 631-640, 2013
20. Sun S, Ning X, Zhai Y, Du R, Lu Y, He L, Li R, Wu W, Sun W, Wang H: Egr-1 mediates chronic hypoxia-induced renal interstitial fibrosis via the PKC/ERK pathway. Am J Nephrol 39: 436-448, 2014
21. Lovgren AK, Kovacs JJ, Xie T, Potts EN, Li Y, Foster WM, Liang J, Meltzer EB, Jiang D, Lefkowitz RJ, Noble PW: b-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci Transl Med 3: 74ra23, 2011
22. Kamal FA, Mickelsen DM, Wegman KM, Travers JG, Moalem J, Hammes SR, Smrcka AV, Blaxall BC: Simultaneous adrenal and cardiac g-protein-coupled receptor-gbg inhibition halts heart failure progression. J AmColl Cardiol 63: 2549-2557, 2014
23. Brinks H, Boucher M, Gao E, Chuprun JK, Pesant S, Raake PW, Huang ZM, Wang X, Qiu G, Gumpert A, Harris DM, Eckhart AD, Most P, Koch WJ: Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res 107: 1140-1149, 2010
24. Fan Q, Chen M, Zuo L, Shang X, Huang MZ, Ciccarelli M, Raake P, Brinks H, Chuprun KJ, Dorn GW2nd, Koch WJ, Gao E:Myocardial ablation of G protein-coupled receptor kinase 2 (GRK2) decreases ischemia/reperfusion injury through an anti-intrinsic apoptotic pathway. PLoS One 8: e66234, 2013
25. Piao L, Fang YH, Parikh KS, Ryan JJ, D'Souza KM, Theccanat T, Toth PT, Pogoriler J, Paul J, Blaxall BC, Akhter SA, Archer SL: GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: Therapeutic implications in pulmonary hypertension. Circulation 126: 2859-2869, 2012
26. Andress DL, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan DE: Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 91: 739-742, 2012
27. Dhaun N, Goddard J, Webb DJ: The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17: 943-955, 2006
28. Dhaun N, Webb DJ: The road from AKI to CKD: The role of endothelin. Kidney Int 84: 637-638, 2013
29. Kohan DE: Endothelins in the normal and diseased kidney.AmJ Kidney Dis 29: 2-26, 1997
30. Zager RA, Johnson AC, Andress D, Becker K: Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 84: 703-712, 2013
31. Zhao Q, Huang H, Wang X, Wang X, Dai Z, Wan P, Guo Z, Yu S, Tang Y, Huang C: Changes of serum neurohormone after renal sympathetic denervation in dogs with pacing-induced heart failure. Int J Clin Exp Med 7: 4024-4030, 2014
32. Ahmed MS, Wong CF, Pai P: Cardiorenal syndrome - a new classification and current evidence on itsmanagement. Clin Nephrol 74: 245-257, 2010
33. Jönsson S, Agic MB, Narfström F, Melville JM, Hultström M: Renal neurohormonal regulation in heart failure decompensation. Am J Physiol Regul Integr Comp Physiol 307: R493-R497, 2014
34. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K: Cardiorenal syndrome: Pathophysiology and potential targets for clinical management. Nat Rev Nephrol 9: 99-111, 2013
35. Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C, McCullough PA: Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: Workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 182: 117-136, 2013
36. Kohan DE, Pollock DM: Endothelin antagonists for diabetic and nondiabetic chronic kidney disease. Br J Clin Pharmacol 76: 573-579, 2013
37. Eddy AA: Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011) 4: 2-8, 2014
38. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa- Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH: The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25: 1083-1093, 2014
39. Forbes JM, Jandeleit-Dahm K, Allen TJ, Hewitson TD, Becker GJ, Jones CL: Endothelin and endothelin A/B receptors are increased after ischaemic acute renal failure. Exp Nephrol 9: 309-316, 2001
40. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A: Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 106: 2806-2811, 2009
41. Green DS, Rupasinghe C, Warburton R, Wilson JL, Sallum CO, Taylor L, Yatawara A, Mierke D, Polgar P, Hill N: A cell permeable peptide targeting the intracellular loop 2 of endothelin B receptor reduces pulmonary hypertension in a hypoxic rat model. PLoS One 8: e81309, 2013
42. Meier KE: Arrestins as signaling modulators: The plot thickens: focus on "Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptormediated cell signaling andmigration in arterial smooth muscle." Am J Physiol Cell Physiol 302: C721-C722, 2012
43. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, Liu W, Molina CA, Sadoshima J, Blaxall BC, Berk BC, Yan C: A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A 102: 14771-14776, 2005
44. Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA: Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation 111: 591-597, 2005
45. Yan C, Ding B, Shishido T, Woo CH, Itoh S, Jeon KI, Liu W, Xu H, McClain C, Molina CA, Blaxall BC, Abe J: Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res 100: 510-519, 2007
46. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543, 2003
47. Casey LM, Pistner AR, Belmonte SL, Migdalovich D, Stolpnik O, Nwakanma FE, Vorobiof G, Dunaevsky O, Matavel A, Lopes CM, Smrcka AV, Blaxall BC: Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res 107: 532-539, 2010
48. Blaxall BC, Spang R, Rockman HA, Koch WJ: Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol Genomics 15: 105-114, 2003
49. Bullard TA, Protack TL, Aguilar F, Bagwe S, Massey HT, Blaxall BC: Identification of Nogo as a novel indicator of heart failure. Physiol Genomics 32: 182-189, 2008
50. Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJ: Differential gene expression and genomic patient stratification following left ventricular assist device support. J AmColl Cardiol 41: 1096-1106, 2003
51. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade-Gordon P, Kotzsch M, Spring D, Luther T, Abe J, Pohlman TH, Verrier ED, Blaxall BC, Mackman N: Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 116: 2298-2306, 2007